Small Molecules
17 December 2014
Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients17 December 2014
Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus17 December 2014
Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors17 December 2014
Poxel Announces Positive Top Line Results for Its Antidiabetic Agent Imeglimin in a Phase 2b Dose-Ranging Trial17 December 2014
Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington’s Disease16 December 2014
Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS16 December 2014
NewGen Therapeutics Targeted Anti-Cancer Drug, NT-113, Demonstrates Compelling Activity in Glioblastoma Xenograft Models16 December 2014
Galapagos regains full rights to GPR84 inhibitor GLPG120515 December 2014
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses15 December 2014
Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia15 December 2014
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source15 December 2014
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits13 December 2014
Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer12 December 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX14012 December 2014
Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium12 December 2014
Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS12 December 2014
Galapagos selects second component of its investigational cystic fibrosis combination treatment11 December 2014
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer11 December 2014
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential for Centanafadine Compared to Stimulants Used for Adult ADHD11 December 2014
X-Chem and Alexion Collaborate to Discover Novel Therapeutic Candidates to Treat Patients with Severe and Ultra-Rare DisordersNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports